Seasonal allergic or perennial rhinitis: After initial priming of the MODEXA nasal spray (usually 10 sprays, until a uniform spray is released), each spray delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate equivalent to 50 mcg mometasone furoate. Prior to administration of the first dose, shake container well and actuate pump well before each use. If the product has not been used for 7 days or longer, it should be reprimed before next use.
Adults (including geriatric patients) and children 12 years of age and older: The usual recommended dose for prophylaxis and treatment is 2 sprays (50 mcg/spray) in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, dose reduction to 1 spray in each nostril (total dose 100 mcg) may be effective for maintenance.
If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of 4 sprays in each nostril once daily (total dose 400 mcg). Dose reduction is recommended following control of symptoms.
Children between the ages of 2 through 11 years: The usual recommended dose is 1 spray (50 mcg/spray) in each nostril once daily (total dose 100 mcg).
Administration to young children should be aided by an adult.
Nasal polyposis: Adults (including geriatric patients) and adolescents 18 years of age and older: The usual recommended starting dose for polyposis is 2 sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 400 mcg). Once symptoms are adequately controlled, dose reduction to two sprays in each nostril once daily (total daily dose 200 mcg) is recommended. Efficacy and safety of MODEXA nasal spray for the treatment of nasal polyps were four months in duration.
Treatment of mild to moderate uncomplicated acute rhinosinusitis: The usual recommended dose for acute rhinosinusitis is two sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 400 mcg). If symptoms worsen during treatment, the patient should be advised to consult their physician.
Patients should not use MODEXA nasal spray without an antibiotic if bacterial infection of the sinuses is present or suspected.
If signs or symptoms of severe bacterial infection are observed during treatment (such as fever, persistent severe unilateral facial/tooth pain, orbital or peri-orbital facial swelling, or worsening of symptoms after an initial improvement), the patient should be advised to consult their physician immediately, at which time the physician may advise the patient to stop using MODEXA nasal spray. Safety and efficacy of MODEXA nasal spray in the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis beyond 15 days have not been evaluated.
The therapeutic effects of corticosteroids, unlike those of decongestants, are not immediate. Since the effect of MODEXA nasal spray depends on its regular use, patients should be instructed to take the nasal inhalation at regular intervals and not, as with other nasal sprays, as they feel necessary.
In the presence of excessive nasal mucous secretion or edema of the nasal mucosa, the drug may fail to reach the site of action. In such cases, it is adviseable to use a nasal vasoconstrictor for 2 to 3 days prior to starting treatment with MODEXA nasal spray. Patients should be instructed on the correct method of use, which is to blow the nose, then insert the nozzle carefully into the nostril, compress the opposite nostril and actuate the spray while inspiring through the nose, with the mouth closed.